{
  "id": 3363939,
  "title": "'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer",
  "url": "https://urgent.news/2026/08/25/practice-changing-data-expand-zanidatamabs-approval-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-25T21:15:20.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/othercancers/122757"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA approved zanidatamab (Ziihera) plus tislelizumab (Tevimbra) and chemotherapy as first-line treatment for unresectable/metastatic HER2-positive gastroesophageal cancer. The approval stipulates use in adults with unresectable...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}